Shared posts

10 Jul 13:44

MURAMYL DIPEPTIDE CAUSES MITOCHONDRIAL DYSFUNCTION AND INTESTINAL INFLAMMATORY CYTOKINE RESPONSES IN RATS

by Lu-Jia Zhao

Shock. 2024 Jul 1;62(1):139-145. doi: 10.1097/SHK.0000000000002369. Epub 2024 Mar 28.

ABSTRACT

Introduction: Intestinal flora and the translocation of its products, such as muramyl dipeptide (MDP), are common causes of sepsis. MDP is a common activator of the intracellular pattern recognition receptor NOD2, and MDP translocation can cause inflammatory damage to the small intestine and systemic inflammatory responses in rats. Therefore, this study investigated the effects of MDP on the intestinal mucosa and distant organs during sepsis and the role of the NOD2/AMPK/LC3 pathway in MDP-induced mitochondrial dysfunction in the intestinal epithelium. Methods: Fifty male Sprague Dawley rats were randomly divided into five treatment groups: lipopolysaccharide (LPS) only, 1.5 and 15 mg/kg MDP+LPS, and 1.5 and 15 mg/kg MDP+short-peptide enteral nutrition (SPEN)+LPS. The total caloric intake was the same per group. The rats were euthanized 24 h after establishing the model, and peripheral blood and small intestinal mucosal and lung tissues were collected. Results: Compared to the LPS group, both MDP+LPS groups had aggravated inflammatory damage to the intestinal mucosal and lung tissues, increased IL-6 and MDP production, increased NOD2 expression, decreased AMPK and LC3 expression, increased mitochondrial reactive oxygen species production, and decreased mitochondrial membrane potential. Compared to the MDP+LPS groups, the MDP+SPEN+LPS groups had decreased IL-6 and MDP production, increased AMPK and LC3 protein expression, and protected mitochondrial and organ functions. Conclusions: MDP translocation reduced mitochondrial autophagy by regulating the NOD2/AMPK/LC3 pathway, causing mitochondrial dysfunction. SPEN protected against MDP-induced impairment of intestinal epithelial mitochondrial function during sepsis.

PMID:38546380 | DOI:10.1097/SHK.0000000000002369

09 Jul 21:20

Metabolic profiling of single cells by exploiting NADH and FAD fluorescence via flow cytometry

by Ariful Haque Abir

Mol Metab. 2024 Jul 4:101981. doi: 10.1016/j.molmet.2024.101981. Online ahead of print.

ABSTRACT

The metabolism of different cells within the same microenvironment can differ and dictate physiological or pathological adaptions. Current single-cell analysis methods of metabolism are not label-free. The study introduces a label-free, live-cell analysis method assessing endogenous fluorescence of NAD(P)H and FAD in surface-stained cells by flow cytometry. OxPhos inhibition, mitochondrial uncoupling, glucose exposure, genetic inactivation of glucose uptake and mitochondrial respiration alter the optical redox ratios of FAD and NAD(P)H as measured by flow cytometry. Those alterations correlate strongly with measurements obtained by extracellular flux analysis. Consequently, metabolically distinct live B-cell populations can be resolved, showing that human memory B-cells from peripheral blood exhibit a higher glycolytic flexibility than naïve B cells. Moreover, the comparison of blood-derived B- and T-lymphocytes from healthy donors and rheumatoid arthritis patients unleashes rheumatoid arthritis-associated metabolic traits in human naïve and memory B-lymphocytes. Taken together, these data show that the optical redox ratio can depict metabolic differences in distinct cell populations by flow cytometry.

PMID:38971403 | DOI:10.1016/j.molmet.2024.101981

08 Jul 14:43

Metabolic profiling of single cells by exploiting NADH and FAD fluorescence via flow cytometry

by Ariful Haque Abir

Mol Metab. 2024 Jul 4;87:101981. doi: 10.1016/j.molmet.2024.101981. Online ahead of print.

ABSTRACT

OBJECTIVE: The metabolism of different cells within the same microenvironment can differ and dictate physiological or pathological adaptions. Current single-cell analysis methods of metabolism are not label-free.

METHODS: The study introduces a label-free, live-cell analysis method assessing endogenous fluorescence of NAD(P)H and FAD in surface-stained cells by flow cytometry.

RESULTS: OxPhos inhibition, mitochondrial uncoupling, glucose exposure, genetic inactivation of glucose uptake and mitochondrial respiration alter the optical redox ratios of FAD and NAD(P)H as measured by flow cytometry. Those alterations correlate strongly with measurements obtained by extracellular flux analysis. Consequently, metabolically distinct live B-cell populations can be resolved, showing that human memory B-cells from peripheral blood exhibit a higher glycolytic flexibility than naïve B cells. Moreover, the comparison of blood-derived B- and T-lymphocytes from healthy donors and rheumatoid arthritis patients unleashes rheumatoid arthritis-associated metabolic traits in human naïve and memory B-lymphocytes.

CONCLUSIONS: Taken together, these data show that the optical redox ratio can depict metabolic differences in distinct cell populations by flow cytometry.

PMID:38971403 | DOI:10.1016/j.molmet.2024.101981

08 Jul 14:34

Structural investigations on the mitochondrial uncouplers niclosamide and FCCP

by Mei Ying Ng

FEBS Open Bio. 2024 Jul;14(7):1057-1071. doi: 10.1002/2211-5463.13817. Epub 2024 May 15.

ABSTRACT

There has been renewed interest in using mitochondrial uncoupler compounds such as niclosamide and carbonyl cyanide p-(trifluoromethoxy)phenylhydrazone (FCCP) for the treatment of obesity, hepatosteatosis and diseases where oxidative stress plays a role. However, both FCCP and niclosamide have undesirable effects that are not due to mitochondrial uncoupling, such as inhibition of mitochondrial oxygen consumption by FCCP and induction of DNA damage by niclosamide. Through structure-activity analysis, we identified FCCP analogues that do not inhibit mitochondrial oxygen consumption but still provided good, although less potent, uncoupling activity. We also characterized the functional role of the niclosamide 4'-nitro group, the phenolic hydroxy group and the anilide amino group in mediating uncoupling activity. Our structural investigations provide important information that will aid further drug development.

PMID:38750619 | PMC:PMC11216929 | DOI:10.1002/2211-5463.13817

03 Jul 16:24

High-throughput discovery of MHC class I- and II-restricted T cell epitopes using synthetic cellular circuits

by Ayano C. Kohlgruber

Nature Biotechnology, Published online: 02 July 2024; doi:10.1038/s41587-024-02248-6

T cell-specific antigens are discovered at high throughput without killing target cells.
02 Jul 16:06

Predicting glycan structure from tandem mass spectrometry via deep learning

by James Urban

Nature Methods, Published online: 01 July 2024; doi:10.1038/s41592-024-02314-6

CandyCrunch is a deep learning-based tool for predicting glycan structures from tandem mass spectrometry data. The paper also introduces CandyCrumbs that automatically annotates fragment ions in higher-order tandem mass spectrometry spectra.
27 Jun 17:23

Personalized cancer vaccines from bacteria-derived outer membrane vesicles with antibody-mediated persistent uptake by dendritic cells

by Jie Liang

Fundam Res. 2021 Dec 22;2(1):23-36. doi: 10.1016/j.fmre.2021.11.032. eCollection 2022 Jan.

ABSTRACT

Nanocarriers with intrinsic immune adjuvant properties can activate the innate immune system while delivering tumor antigen, thus efficiently facilitating antitumor adaptive immunity. Bacteria-derived outer membrane vesicles (OMVs) are an excellent candidate due to their abundance of pathogen associated molecular patterns. However, during the uptake of OMVs by dendritic cells (DCs), the interaction between lipopolysaccharide and toll-like receptor 4 induces rapid DC maturation and uptake blockage, a phenomenon we refer to as "maturation-induced uptake obstruction" (MUO). Herein we decorated OMV with the DC-targeting αDEC205 antibody (OMV-DEC), which endowed the nanovaccine with an uptake mechanism termed as "not restricted to maturation via antibody modifying" (Normandy), thereby overcoming the MUO phenomenon. We also proved the applicability of this nanovaccine in identifying the human tumor neoantigens through rapid antigen display. In summary, this engineered OMV represents a powerful nanocarrier for personalized cancer vaccines, and this antibody modification strategy provides a reference to remodel the DC uptake pattern in nanocarrier design.

PMID:38933907 | PMC:PMC11197747 | DOI:10.1016/j.fmre.2021.11.032

27 Jun 13:42

A novel controlled metabolic accelerator for the treatment of obesity-related heart failure with preserved ejection fraction: Rationale and design of the Phase 2a HuMAIN trial

by Dalane W Kitzman
Brianna Dalesandro

my company

Eur J Heart Fail. 2024 Jun 26. doi: 10.1002/ejhf.3305. Online ahead of print.

ABSTRACT

AIMS: Compared with those without obesity, patients with obesity-related heart failure with preserved ejection fraction (HFpEF) have worse symptoms, haemodynamics, and outcomes. Current weight loss strategies (diet, drug, and surgical) work through decreased energy intake rather than increased expenditure and cause significant loss of skeletal muscle mass in addition to adipose tissue. This may have adverse implications for patients with HFpEF, who already have reduced skeletal muscle mass and function and high rates of physical frailty. Mitochondrial uncoupling agents may have unique beneficial effects by producing weight loss via increased catabolism rather than reduced caloric intake, thereby causing loss of adipose tissue while sparing skeletal muscle. HU6 is a controlled metabolic accelerator that is metabolized to the mitochondrial uncoupling agent 2,4-dinotrophenol. HU6 selectively increases carbon oxidation from fat and glucose while also decreasing toxic reactive oxygen species (ROS) production. In addition to sparing skeletal muscle loss, HU6 may have other benefits relevant to obesity-related HFpEF, including reduced specific tissue depots contributing to HFpEF; improved glucose utilization; and reduction in systemic inflammation via both decreased ROS production from mitochondria and decreased cytokine elaboration from excess, dysfunctional adipose.

METHODS: We describe the rationale and design of HuMAIN-HFpEF, a Phase 2a randomized, double-blind, placebo-controlled, dose-titration, parallel-group trial in patients with obesity-related HFpEF to evaluate the effects of HU6 on weight loss, body composition, exercise capacity, cardiac structure and function, metabolism, and inflammation, and identify optimal dosage for future Phase 3 trials.

CONCLUSIONS: HuMAIN will test a promising novel agent for obesity-related HFpEF.

PMID:38924328 | DOI:10.1002/ejhf.3305

27 Jun 13:03

Bacterial barcoding facilitates plant microbiome studies

by Hualan Liu

Nature Reviews Microbiology, Published online: 26 June 2024; doi:10.1038/s41579-024-01069-3

This month’s Genome Watch highlights the use of genetic barcoding towards a better understanding of plant–microorganism interactions and colonization dynamics.
27 Jun 12:59

Journal retracts influential cancer microbiome paper

by Catherine Offord
Claim that a blood sample’s mix of microbes can reveal a tumor spawned other research and a company to commercialize the findings
26 Jun 18:02

Halenaquinol Blocks Staphylococcal Protein A Anchoring on Cell Wall Surface by Inhibiting Sortase A in Staphylococcus aureus

by Jaepil Lee

Mar Drugs. 2024 Jun 10;22(6):266. doi: 10.3390/md22060266.

ABSTRACT

Sortase A (SrtA) is a cysteine transpeptidase that binds to the periplasmic membrane and plays a crucial role in attaching surface proteins, including staphylococcal protein A (SpA), to the peptidoglycan cell wall. Six pentacyclic polyketides (1-6) were isolated from the marine sponge Xestospongia sp., and their structures were elucidated using spectroscopic techniques and by comparing them to previously reported data. Among them, halenaquinol (2) was found to be the most potent SrtA inhibitor, with an IC50 of 13.94 μM (4.66 μg/mL). Semi-quantitative reverse transcription PCR data suggest that halenaquinol does not inhibit the transcription of srtA and spA, while Western blot analysis and immunofluorescence microscopy images suggest that it blocks the cell wall surface anchoring of SpA by inhibiting the activity of SrtA. The onset and magnitude of the inhibition of SpA anchoring on the cell wall surface in S. aureus that has been treated with halenaquinol at a value 8× that of the IC50 of SrtA are comparable to those for an srtA-deletion mutant. These findings contribute to the understanding of the mechanism by which marine-derived pentacyclic polyketides inhibit SrtA, highlighting their potential as anti-infective agents targeting S. aureus virulence.

PMID:38921577 | PMC:PMC11204543 | DOI:10.3390/md22060266

26 Jun 18:01

A Gram-negative-selective antibiotic that spares the gut microbiome

by Kristen A Muñoz

Nature. 2024 Jun;630(8016):429-436. doi: 10.1038/s41586-024-07502-0. Epub 2024 May 29.

ABSTRACT

Infections caused by Gram-negative pathogens are increasingly prevalent and are typically treated with broad-spectrum antibiotics, resulting in disruption of the gut microbiome and susceptibility to secondary infections1-3. There is a critical need for antibiotics that are selective both for Gram-negative bacteria over Gram-positive bacteria, as well as for pathogenic bacteria over commensal bacteria. Here we report the design and discovery of lolamicin, a Gram-negative-specific antibiotic targeting the lipoprotein transport system. Lolamicin has activity against a panel of more than 130 multidrug-resistant clinical isolates, shows efficacy in multiple mouse models of acute pneumonia and septicaemia infection, and spares the gut microbiome in mice, preventing secondary infection with Clostridioides difficile. The selective killing of pathogenic Gram-negative bacteria by lolamicin is a consequence of low sequence homology for the target in pathogenic bacteria versus commensals; this doubly selective strategy can be a blueprint for the development of other microbiome-sparing antibiotics.

PMID:38811738 | DOI:10.1038/s41586-024-07502-0

26 Jun 18:01

CRISPR screens of tumor-infiltrating NK cells identify genetic checkpoints for CAR-NK therapy

Nature Biotechnology, Published online: 25 June 2024; doi:10.1038/s41587-024-02319-8

We use a CRISPR screening platform based on adeno-associated virus and the Sleeping Beauty transposon (AAV-SB-CRISPR) to perform in vivo CRISPR screens in primary natural killer (NK) cells across four different tumor models, and identify calcium homeostasis modulator family member 2 (CALHM2) as an NK cellular checkpoint protein.
26 Jun 18:00

Ultrasound‐Mediated Antibiotic Delivery to In Vivo Biofilm Infections: A Review

by Jamie D. Liu, Kelly E. VanTreeck, William A. Marston, Virginie Papadopoulou, Sarah E. Rowe
Ultrasound-Mediated Antibiotic Delivery to In Vivo Biofilm Infections: A Review

Bacterial biofilms pose a significant clinical challenge because they are highly resistant to host immune responses and antibiotic treatments. This review delves into the reasons behind the difficulty in treating biofilms and investigates the potential of ultrasound-mediated drug delivery as a method to address various in vivo biofilm infections.


Abstract

Bacterial biofilms are a significant concern in various medical contexts due to their resilience to our immune system as well as antibiotic therapy. Biofilms often require surgical removal and frequently lead to recurrent or chronic infections. Therefore, there is an urgent need for improved strategies to treat biofilm infections. Ultrasound-mediated drug delivery is a technique that combines ultrasound application, often with the administration of acoustically-active agents, to enhance drug delivery to specific target tissues or cells within the body. This method involves using ultrasound waves to assist in the transportation or activation of medications, improving their penetration, distribution, and efficacy at the desired site. The advantages of ultrasound-mediated drug delivery include targeted and localized delivery, reduced systemic side effects, and improved efficacy of the drug at lower doses. This review scrutinizes recent advances in the application of ultrasound-mediated drug delivery for treating biofilm infections, focusing on in vivo studies. We examine the strengths and limitations of this technology in the context of wound infections, device-associated infections, lung infections and abscesses, and discuss current gaps in knowledge and clinical translation considerations.

21 Jun 16:10

The potential of bacterial anti-phagocytic proteins in suppressing the clearance of extracellular vesicles mediated by host phagocytosis

by Jiacong Sun

Front Immunol. 2024 Jun 6;15:1418061. doi: 10.3389/fimmu.2024.1418061. eCollection 2024.

ABSTRACT

Extracellular vesicles (EVs), characterized by low immunogenicity, high biocompatibility and targeting specificity along with excellent blood-brain barrier permeability, are increasingly recognized as promising drug delivery vehicles for treating a variety of diseases, such as cancer, inflammation and viral infection. However, recent findings demonstrate that the intracellular delivery efficiency of EVs fall short of expectations due to phagocytic clearance mediated by the host mononuclear phagocyte system through Fcγ receptors, complement receptors as well as non-opsonic phagocytic receptors. In this text, we investigate a range of bacterial virulence proteins that antagonize host phagocytic machinery, aiming to explore their potential in engineering EVs to counteract phagocytosis. Special emphasis is placed on IdeS secreted by Group A Streptococcus and ImpA secreted by Pseudomonas aeruginosa, as they not only counteract phagocytosis but also bind to highly upregulated surface biomarkers αVβ3 on cancer cells or cleave the tumor growth and metastasis-promoting factor CD44, respectively. This suggests that bacterial anti-phagocytic proteins, after decorated onto EVs using pre-loading or post-loading strategies, can not only improve EV-based drug delivery efficiency by evading host phagocytosis and thus achieve better therapeutic outcomes but also further enable an innovative synergistic EV-based cancer therapy approach by integrating both phagocytosis antagonism and cancer targeting or deactivation.

PMID:38903499 | PMC:PMC11186983 | DOI:10.3389/fimmu.2024.1418061

21 Jun 15:06

Bispecific antibodies targeting two glycoproteins on SFTSV exhibit synergistic neutralization and protection in a mouse model

by Zhen ChangDan GaoLiying LiaoJunqing SunGen ZhangXue ZhangFeiran WangChunrui LiBabayemi Olawale OladejoShihua LiYan ChaiYongfei HuXuancheng LuHaixia XiaoJianxun QiZhihai ChenFeng GaoYan WuaDepartment of Pathogen Microbiology, School of Basic Medical Sciences, Capital Medical University, Beijing 100069, ChinabChinese Academy of Sciences Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, ChinacCollege of Veterinary Medicine, Shanxi Agricultural University, Jinzhong, Shanxi 030801, ChinadFaculty of Health Sciences, University of Macau, Macau SAR 999078, ChinaeDepartment of Microbiology, Federal University of Technology, PMB704, Akure, NigeriafCollege of Veterinary Medicine, China Agricultural University, Beijing 100193, ChinagNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Chinese Center for Disease Control and Prevention, Beijing 102206, ChinahLaboratory of Protein Engineering and Vaccines, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Tianjin 300308, ChinaiCenter of Infectious Disease, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
Proceedings of the National Academy of Sciences, Volume 121, Issue 24, June 2024.
21 Jun 15:03

The molecular architecture of Lactobacillus S-layer: Assembly and attachment to teichoic acids

by Theo SagmeisterNina GubensäkChristoph BuhlhellerChristoph GriningerMarkus EderAnđela ÐordićClaudia MillánAna MedinaPedro Alejandro Sánchez MurciaFrancesca BerniUlla HynönenDjenana VejzovićElisabeth DamischNatalia KulminskayaLukas PetrowitschMonika ObererAiri PalvaNermina MalanovićJeroen CodéeWalter KellerIsabel UsónTea Pavkov-KelleraInstitute of Molecular Biosciences, University of Graz, Graz, Austria 8010bStructural Biology Unit, Institute of Molecular Biology of Barcelona, Spanish National Research Council, Barcelona 08028, SpaincLaboratory of Computer-Aided Molecular Design, Division of Medicinal Chemistry, Otto-Loewi Research Center, Medical University of Graz, Graz, Austria 8010dDepartment of Bio-Organic Synthesis, Leiden Institute of Chemistry, Leiden University, Leiden 2333, The NetherlandseDepartment of Basic Veterinary Sciences, Division of Microbiology and Epidemiology, University of Helsinki, Helsinki 00100, FinlandfField of Excellence BioHealth, University of Graz, Graz 8010, AustriagBioTechMed-Graz, University of Graz, Graz 8010, AustriahInstitució Catalana de Recerca i Estudis Avançats, Barcelona 08003, Spain
Proceedings of the National Academy of Sciences, Volume 121, Issue 24, June 2024.
21 Jun 14:57

Interactions between diet and gut microbiota in cancer

by Geicho Nakatsu

Nature Microbiology, Published online: 21 June 2024; doi:10.1038/s41564-024-01736-4

In this Perspective, the authors discuss current knowledge of microbiome–diet–cancer interactions from preclinical studies and clinical trials and the outlook for potential dietary interventions.
21 Jun 14:57

Guiding antibiotics towards their target using bacteriophage proteins

by Xinghong Zhao

Nature Communications, Published online: 20 June 2024; doi:10.1038/s41467-024-49603-4

Zhao et al. demonstrate a strategy that delivers antibiotics to the site of infection using proteins from bacteriophages, which naturally target bacteria. This approach helps the antibiotic regain activity against conventionally resistant strains.
21 Jun 14:50

Mitochondria and cell death

by Hannah L. Glover

Nature Cell Biology, Published online: 20 June 2024; doi:10.1038/s41556-024-01429-4

Several processes of regulated cell death engage or use mitochondria, which are thus central hubs that not only coordinate cell death but also elicit non-lethal signalling mediated by mitochondrial outer membrane permeabilization.
20 Jun 21:20

Old drugs new tricks—novel approach shows 'enormous potential' for rapid antibiotic discovery

An innovative project to re-purpose existing drugs for their potential as antibiotics has uncovered a highly promising candidate with a potent and unique way of killing drug resistant bacteria.
19 Jun 17:29

Novel drug targets and molecular mechanisms for sarcopenia based on systems biology

by Atakan Burak Ceyhan

Biomed Pharmacother. 2024 Jul;176:116920. doi: 10.1016/j.biopha.2024.116920. Epub 2024 Jun 13.

ABSTRACT

Sarcopenia is a major public health concern among older adults, leading to disabilities, falls, fractures, and mortality. This study aimed to elucidate the pathophysiological mechanisms of sarcopenia and identify potential therapeutic targets using systems biology approaches. RNA-seq data from muscle biopsies of 24 sarcopenic and 29 healthy individuals from a previous cohort were analysed. Differential expression, gene set enrichment, gene co-expression network, and topology analyses were conducted to identify target genes implicated in sarcopenia pathogenesis, resulting in the selection of 6 hub genes (PDHX, AGL, SEMA6C, CASQ1, MYORG, and CCDC69). A drug repurposing approach was then employed to identify new pharmacological treatment options for sarcopenia (clofibric-acid, troglitazone, withaferin-a, palbociclib, MG-132, bortezomib). Finally, validation experiments in muscle cell line (C2C12) revealed MG-132 and troglitazone as promising candidates for sarcopenia treatment. Our approach, based on systems biology and drug repositioning, provides insight into the molecular mechanisms of sarcopenia and offers potential new treatment options using existing drugs.

PMID:38876054 | DOI:10.1016/j.biopha.2024.116920

19 Jun 13:41

Development of non-β-Lactam covalent allosteric inhibitors targeting PBP2a in Methicillin-Resistant Staphylococcus aureus

by Bogdan M Benin

bioRxiv [Preprint]. 2024 May 30:2024.05.29.596450. doi: 10.1101/2024.05.29.596450.

ABSTRACT

Methicillin-resistant Staphylococcus aureus (MRSA), a Gram-positive bacterial pathogen, continues to pose a serious threat to the current public health system in our society. The high level of resistance to β-lactam antibiotics in MRSA is attributed to the expression of penicillin-binding protein 2a (PBP2a), which catalyzes cell wall cross-linking. According to numerous research reports, the activity of the PBP2a protein is known to be regulated by an allosteric site distinct from the active site where cell wall cross-linking occurs. Here, we conducted a screening of 113 compounds containing a 1,3,4-oxadiazole core to design new covalent inhibitors targeting the allosteric site of PBP2a and establish their structural-activity relationship. The stereochemically selective synthesis of sulfonyl oxadiazole compounds identified in the initial screening resulted in a maximum eightfold enhancement in cell inhibition activity. The sulfonyl oxadiazole-based compounds formulated as PEG-based ointments, with low toxicity test results on human cells (CC 50 : >78μM), demonstrated potent antimicrobial effects not only in a mouse skin wound infection model but also against oxacillin-resistant clinical isolate MRSA (IC 50 ≈ 1μM), as evidenced by the results. Furthermore, additional studies utilizing LC-MS/MS and in-silico approaches clearly support the allosteric site covalent binding mechanism through the nucleophilic aromatic substitution (S N Ar) reaction, as well as its association with the closure of the major active site of PBP2a.

PMID:38853829 | PMC:PMC11160701 | DOI:10.1101/2024.05.29.596450

19 Jun 13:31

Secreted antigen A peptidoglycan hydrolase is essential for Enterococcus faecium cell separation and priming of immune checkpoint inhibitor therapy

by Steven Klupt

Elife. 2024 Jun 10;13:RP95297. doi: 10.7554/eLife.95297.

ABSTRACT

Enterococcus faecium is a microbiota species in humans that can modulate host immunity (Griffin and Hang, 2022), but has also acquired antibiotic resistance and is a major cause of hospital-associated infections (Van Tyne and Gilmore, 2014). Notably, diverse strains of E. faecium produce SagA, a highly conserved peptidoglycan hydrolase that is sufficient to promote intestinal immunity (Rangan et al., 2016; Pedicord et al., 2016; Kim et al., 2019) and immune checkpoint inhibitor antitumor activity (Griffin et al., 2021). However, the functions of SagA in E. faecium were unknown. Here, we report that deletion of sagA impaired E. faecium growth and resulted in bulged and clustered enterococci due to defective peptidoglycan cleavage and cell separation. Moreover, ΔsagA showed increased antibiotic sensitivity, yielded lower levels of active muropeptides, displayed reduced activation of the peptidoglycan pattern-recognition receptor NOD2, and failed to promote cancer immunotherapy. Importantly, the plasmid-based expression of SagA, but not its catalytically inactive mutant, restored ΔsagA growth, production of active muropeptides, and NOD2 activation. SagA is, therefore, essential for E. faecium growth, stress resistance, and activation of host immunity.

PMID:38857064 | PMC:PMC11164530 | DOI:10.7554/eLife.95297

19 Jun 13:24

Septic Shock: LPS tolerance protects mitochondrial biogenesis and respiration

by Andre Augusto Botêga Silva

Shock. 2024 Jun 18. doi: 10.1097/SHK.0000000000002399. Online ahead of print.

ABSTRACT

Mitochondrial dysfunction is a recognized feature of sepsis, characterized by ultrastructural damage, diminished oxidative phosphorylation, and depletion of mitochondrial antioxidant capacity observed in deceased septic patients. Lipopolysaccharide (LPS) tolerance induces a controlled response to sepsis. This study aimed to evaluate the function of tolerant mitochondria after cecal ligation and puncture (CLP)-induced sepsis. Mytochondrial oxygen consumption was determined using polarography. Extraction and quantification of RNA for the expression of Tfam, Nrf-1 and Ppargc-1α; and Respiratory complex activity were measured. CLP-tolerant animals presented preserved respiratory rates of S3 and S4 and a ratio of respiratory control (RCR) compared to CLP non-tolerant animals with reduced oxidative phosphorylation and increased uncoupled respiration. Complex I Vmax was reduced in septic animals; however, CLP animals sustained normal Vmax. Mitochondrial biogenesis was preserved in CLP-tolerant animals compared to the CLP-nontolerant group, likely due to increased TFAM expression. LPS tolerance protected septic animals from mitochondrial dysfunction, favoring mitochondrial biogenesis and preserving mitochondrial respiration and respiratory complex I activity.

PMID:38888558 | DOI:10.1097/SHK.0000000000002399

18 Jun 14:59

High resolution long-read telomere sequencing reveals dynamic mechanisms in aging and cancer

by Tobias T. Schmidt

Nature Communications, Published online: 18 June 2024; doi:10.1038/s41467-024-48917-7

Here, the authors developed a method to precisely measure bulk, chromosome arm- and allele-specific human telomere length using nanopore sequencing. They resolve telomere shortening and differences between telomerase- and ALT-positive cancer cells
18 Jun 14:40

[ASAP] Triazole-Bridged Peptides with Enhanced Antimicrobial Activity and Potency against Pathogenic Bacteria

by Joshua Grabeck, Jacob Mayer, Axel Miltz, Michele Casoria, Michael Quagliata, Denise Meinberger, Andreas R. Klatt, Isabelle Wielert, Berenike Maier, Anna Maria Papini, and Ines Neundorf

TOC Graphic

ACS Infectious Diseases
DOI: 10.1021/acsinfecdis.4c00078
17 Jun 17:21

Mycobacterial d-serine impairs TB control

by Maxime Caouaille

Nature Immunology, Published online: 13 June 2024; doi:10.1038/s41590-024-01873-2

Adaptation to hypoxia and immune escape are two hallmarks of Mycobacterium tuberculosis infection. The d-serine isomer has now been identified as a factor produced by M. tuberculosis upon hypoxic conditions, dampening CD8+ T cell responses.
17 Jun 13:49

Theoretical and Experimental Study of the Interaction of Protonophore Uncouplers and Decoupling Agents with Functionally Active Mitochondria

by Victor N Samartsev

Cell Biochem Biophys. 2024 Sep;82(3):2333-2345. doi: 10.1007/s12013-024-01343-4. Epub 2024 Jun 10.

ABSTRACT

The purpose of this work was to quantitatively characterize the effectiveness of oxidative phosphorylation uncouplers and decoupling agents in functionally active mitochondria, taking into account their content in the hydrophobic region of the inner membrane of these organelles. When conducting theoretical studies, it is accepted that uncouplers and decouplers occupy part of the volume of mitochondria to exhibit their activity, which is defined as the effective volume. The following quantities characterizing the action of these reagents are considered: (1) concentrations of reagents that cause double stimulation of mitochondrial respiration in state 4 ( C 200 ); (2) effective distribution coefficient ( E MW ) - the ratio of the amount of reagents in the effective volume of mitochondria and the water volume; (3) the relative amount of reagents associated with the effective volume of mitochondria ( U M / U T ); (4) specific activity of reagents localized in the effective volume of mitochondria ( A M ). We have developed methods for determining these values, based on an analysis of the dependence of the rate of mitochondrial respiration on the concentration of uncouplers and decoupling agents at two different concentrations of mitochondrial protein in the incubation medium. During experimental studies, we compared the effects of the classical protonophore uncouplers 2,4-dinitrophenol (DNP) and сarbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP), the natural uncouplers lauric and palmitic acids, and the natural decouplers α,ω-tetradecanedioic (TDA) and α,ω-hexadecanedioic (HDA) acids that differ both in the structure of the molecule and in the degree of solubility in lipids. Using the developed methods, we have clarified the dependence of the degree of activity of these uncouplers and decoupling agents on the distribution of their molecules between the effective volume of mitochondria and the water volume.

PMID:38856833 | DOI:10.1007/s12013-024-01343-4

17 Jun 13:45

Exploring the multifaceted role of adenosine nucleotide translocase 2 in cellular and disease processes: A comprehensive review

by Tianhui Pan

Life Sci. 2024 Aug 15;351:122802. doi: 10.1016/j.lfs.2024.122802. Epub 2024 Jun 8.

ABSTRACT

Adenosine nucleotide translocases (ANTs) are a family of proteins abundant in the inner mitochondrial membrane, primarily responsible for shuttling ADP and ATP across the mitochondrial membrane. Additionally, ANTs are key players in balancing mitochondrial energy metabolism and regulating cell death. ANT2 isoform, highly expressed in undifferentiated and proliferating cells, is implicated in the development and drug resistance of various tumors. We conduct a detailed analysis of the potential mechanisms by which ANT2 may influence tumorigenesis and drug resistance. Notably, the significance of ANT2 extends beyond oncology, with roles in non-tumor cell processes including blood cell development, gastrointestinal motility, airway hydration, nonalcoholic fatty liver disease, obesity, chronic kidney disease, and myocardial development, making it a promising therapeutic target for multiple pathologies. To better understand the molecular mechanisms of ANT2, this review summarizes the structural properties, expression patterns, and basic functions of the ANT2 protein. In particular, we review and analyze the controversy surrounding ANT2, focusing on its role in transporting ADP/ATP across the inner mitochondrial membrane, its involvement in the composition of the mitochondrial permeability transition pore, and its participation in apoptosis.

PMID:38857656 | DOI:10.1016/j.lfs.2024.122802